Bicara Therapeutics (NASDAQ:BCAX) Given “Overweight” Rating at Cantor Fitzgerald

Bicara Therapeutics (NASDAQ:BCAX)‘s stock had its “overweight” rating reissued by analysts at Cantor Fitzgerald in a research note issued on Thursday,Benzinga reports. They currently have a $13.01 price target on the stock. Cantor Fitzgerald’s price target indicates a potential upside of 0.08% from the stock’s current price.

Other analysts have also recently issued reports about the stock. HC Wainwright upped their target price on shares of Bicara Therapeutics from $42.00 to $45.00 and gave the company a “buy” rating in a research report on Monday, January 27th. Wedbush reaffirmed an “outperform” rating and issued a $31.00 price objective on shares of Bicara Therapeutics in a research note on Wednesday, February 12th. Seven research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Buy” and an average price target of $36.50.

Bicara Therapeutics Stock Performance

BCAX traded down $0.01 during trading hours on Thursday, hitting $13.00. The company’s stock had a trading volume of 265,748 shares, compared to its average volume of 426,274. The firm has a 50-day moving average of $13.35. Bicara Therapeutics has a 12 month low of $11.10 and a 12 month high of $28.09.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Spire Wealth Management acquired a new stake in Bicara Therapeutics during the fourth quarter worth about $31,000. BNP Paribas Financial Markets acquired a new stake in Bicara Therapeutics in the fourth quarter valued at approximately $32,000. Legal & General Group Plc purchased a new stake in shares of Bicara Therapeutics in the fourth quarter valued at approximately $33,000. Summit Investment Advisors Inc. purchased a new stake in Bicara Therapeutics in the 4th quarter worth $35,000. Finally, Virtus ETF Advisers LLC acquired a new position in Bicara Therapeutics during the fourth quarter worth $69,000.

About Bicara Therapeutics

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.